Pfizer launches Sayana Press in U.K.; Barron's sees big upside for Amgen; Kerry urged to press India on patents;

@FiercePharma: Supremes rule in pay-for-delay case: 5-3 vote slaps down AbbVie/Actavis plea for protection from lawsuits over patent settlements. | Follow @FiercePharma

@EricPFierce: India's Wockhardt in serious hurt between FDA import alert and India's decision to pull pain drug. Story | Follow @EricPFierce

> Because of a shortage of doxycycline, the CDC is suggesting providers use it only for conditions where there are no alternatives, which includes rickettsial infections, to prevent Lyme disease and for prevention and treatment of malaria. Report

> U.S. Senate leaders have asked Secretary of State John Kerry to pressure India to stop abusing patents on drugs to benefit its generic drug manufacturers. Story

> Pfizer ($PFE) has launched in the U.K. Sayana Press, a contraceptive that is injected by a nurse or doctor into patients every 13 weeks. Story

> Celgene ($CELG) has received approval in Europe for Revlimid as a treatment for a rare form of blood disease, even as it's offered up more promising data on its multiple myeloma drug pomalidomide. Story

> An extension study further supports the long-term safety of Boehringer Ingelheim's Pradaxa in patients with non-valvular atrial fibrillation. Release

Medical Device News

 @FierceMedDev: Amaranth's dissolving cardiac stent drives $25M fundraising round. Story | Follow @FierceMedDev

 @DamianFierce: ADC superstar Ambrx is reaching out to WuXi to develop a cancer drug of its own. From FierceCRO | Follow @DamianFierce

 @MarkHFierce: Curious to hear from readers--what device and diagnostics companies do you see as major M&A targets through the rest of 2013? LinkedIn discussion | Follow @MarkHFierce

 @MichaelGFierce: Drug-carrying 'nanovolcanoes' make precise delivery structures. From FierceDrugDelivery | Follow @MichaelGFierce

> German court upholds Medtronic's CoreValve heart pump patent. Article

> More diagnostics companies pounce in wake of SCOTUS gene decision. Item

> J&J/Mentor wins U.S. sign-off for silicone breast implant, with conditions. More

Biotech News

 @FierceBiotech: ICYMI: Merck's new R&D chief Perlmutter begins major shakeup. Report | Follow @FierceBiotech

 @JohnCFierce: J&J snags another promising prostate cancer drug in $1B Aragon buyout. News | Follow @JohnCFierce

 @RyanMFierce: 2013 Fierce 15 survey: Tell us who you think will be the next Aragon or privately held biotech to get acquired. Submit your nominations now | Follow @RyanMFierce

 @EmilyMFierce: Inovio says H7N9 bird flu vaccine effective in mice. Article | Follow @EmilyMFierce

> OncoNova files $75M IPO as new offerings sizzle. Story

> Investors snub Elan deals, but buyback win could scuttle hostile offer. Report

> Index Ventures taps Big Pharma-backed fund to hatch anticoagulant upstart. News

CRO News

> Synexus wins Pfizer's favor for South African trials. More

> Ash Stevens signs on for Ariad's blockbuster contender. Item

> Ambrx taps WuXi for HER2-targeting cancer drug. Report

> Almac adding 229 jobs in Irish CMO expansion. Article

> Catalent puts $35M into CMO plant. Story

> MPI teams up with imaging outfits to woo drug developers. News

Biotech IT News

> Berkeley professor: Genomic data leaks seem inevitable. More

> Cancer Research UK mulls multiple video game options. Report

> 23andMe seeks consumer boost in long-range data strategy. Story

> FDA joins chorus of concern about cybersecurity threats. More

> Firm tries startup's tech tricks for clinical trial recruitment. Article

And Finally... Barron's says Amgen's ($AMGN) shares could grow even more than the 43% they have in the last 12 months as it benefits from cost cuts, newer drugs and a share buyback program. Story

Suggested Articles

WuXi AppTec has appointed Celgene CAR-T program veteran David Chang to lead its cell and gene therapy CDMO, WuXi Advanced Therapies.

Maryland-based Emergent BioSolutions has won a $628 million contract with BARDA to manufacture targeted COVID-19 vaccine hopefuls.

About 76% remdesivir patients had at least one point of clinical improvement on a 7-point scale at day 11, versus 66% of patients on standard care.